NCT03373786View on ClinicalTrials.gov

A Study of RG-012 in Subjects With Alport Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 22, 2017

Primary Completion Date

May 20, 2019

Study Completion Date

May 20, 2019

Conditions
Alport Syndrome
Interventions
DRUG

RG012

RG012 in 0.3% sodium chloride

Trial Locations (7)

33604

Eminence Medical & Clinical Research, Tampa

53226

Allegiance Research Specialists, LLC, Wauwatosa

77429

Houston Nephrology Research, Cypress

84107

Utah Kidney Research Institute, Salt Lake City

90022

Academic Medical Research Institute, Los Angeles

91942

eStudySite, La Mesa

92505

Apex Research of Riverside, Riverside

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT03373786 - A Study of RG-012 in Subjects With Alport Syndrome | Biotech Hunter | Biotech Hunter